Frontiers in Pharmacology (Nov 2024)

Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

  • Kehui Meng,
  • Heng Xiang,
  • Meiyu Wu,
  • Ouyang Xie,
  • Andong Li,
  • Chongqing Tan,
  • Xiaomin Wan

DOI
https://doi.org/10.3389/fphar.2024.1382342
Journal volume & issue
Vol. 15

Abstract

Read online

AimsAssessing the cost-effectiveness of Nivolumab with Gemcitabine–Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.MethodsA Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.ResultsThe base-case analysis showed Nivolumab plus Gemcitabine–Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab’s cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine–Cisplatin in aUC treatment.ConclusionNivolumab plus Gemcitabine–Cisplatin is not cost-effective in the treatment of aUC.

Keywords